This is the inaugural meeting of the recently relaunched New Starters Special Interest Group. The aim of this meeting is to provide a relaxed environment for early career statisticians to network and interact with their peers across the industry. We will provide a program of informal talks alongside breakout and ice-breaker sessions in order to facilitate discussion amongst attendees. For this one-day meeting the audience will be peers with similar levels of experience and sessions will include content of interest to statisticians early in their careers. In addition to presentations from fellow statisticians there will be a workshop on estimands and ample opportunity to connect with colleagues across the industry.
We’re compiling a New Starters email distribution list so that we can let members know about future events and ideas for New Starters. Please click here to join the mailing list.
The agenda for the day is as follows:
Propensity Score Matching and Missing Data Analysis Quratul Ann (IQVIA)
Estimands Workshop Maria Efstathiou (IQVIA)
Contrast Statements Marta Bacmaga (IQVIA)
Multiple Imputation Methods for Handling Missingness Sophie Hodge (IQVIA)
Transitioning from Programmer to Biostatisticians Emma Martin (PPD)
Experiences in a Large Pharma Company Xinyi Zhu (GSK)
Clinical Trials in Pregnant Women Tasmin Arnould (Veramed)
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.